CA2224052C - Proteine de la membrane externe de bordetella pertussis - Google Patents

Proteine de la membrane externe de bordetella pertussis Download PDF

Info

Publication number: CA2224052C
Authority: CA; Canada
Prior art keywords: pertactin; component; purified; solution; pertussis
Prior art date: 1990-04-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002224052A

Other languages

English (en)

Other versions

CA2224052A1 (fr

Inventor

John Vose

Gail Jackson

Raafat Fahim

Larry Tan

Pele Chong

Michel Klein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Pasteur Ltd

Original Assignee

Connaught Laboratories Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-04

Filing date

1991-04-03

Publication date

2001-12-18

1990-04-04 Priority claimed from GB909007656A external-priority patent/GB9007656D0/en

1991-04-03 Application filed by Connaught Laboratories Ltd filed Critical Connaught Laboratories Ltd

1991-04-03 Priority to CA002359307A priority Critical patent/CA2359307A1/fr

1991-04-03 Priority claimed from CA002079887A external-priority patent/CA2079887C/fr

1991-10-05 Publication of CA2224052A1 publication Critical patent/CA2224052A1/fr

2001-12-18 Application granted granted Critical

2001-12-18 Publication of CA2224052C publication Critical patent/CA2224052C/fr

2011-04-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

201000005702 Pertussis Diseases 0.000 title description 17
101710116435 Outer membrane protein Proteins 0.000 title description 5
108010021711 pertactin Proteins 0.000 claims abstract description 120
108010081690 Pertussis Toxin Proteins 0.000 claims abstract description 37
241000588832 Bordetella pertussis Species 0.000 claims abstract description 33
229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 19
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 19
239000012614 Q-Sepharose Substances 0.000 claims abstract description 18
102000030621 adenylate cyclase Human genes 0.000 claims abstract description 16
108060000200 adenylate cyclase Proteins 0.000 claims abstract description 16
230000000694 effects Effects 0.000 claims abstract description 15
238000000855 fermentation Methods 0.000 claims abstract description 15
230000004151 fermentation Effects 0.000 claims abstract description 15
229960005486 vaccine Drugs 0.000 claims description 43
239000000243 solution Substances 0.000 claims description 33
102000036639 antigens Human genes 0.000 claims description 32
108091007433 antigens Proteins 0.000 claims description 32
239000000427 antigen Substances 0.000 claims description 31
238000000034 method Methods 0.000 claims description 25
239000007864 aqueous solution Substances 0.000 claims description 11
238000004587 chromatography analysis Methods 0.000 claims description 11
239000000463 material Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
239000011159 matrix material Substances 0.000 claims description 7
238000005342 ion exchange Methods 0.000 claims description 5
241000588807 Bordetella Species 0.000 claims description 4
238000011403 purification operation Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
230000006872 improvement Effects 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
229960000814 tetanus toxoid Drugs 0.000 claims description 3
239000000356 contaminant Substances 0.000 claims description 2
229960003983 diphtheria toxoid Drugs 0.000 claims description 2
238000011109 contamination Methods 0.000 claims 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 abstract description 21
229910052921 ammonium sulfate Inorganic materials 0.000 abstract description 20
239000001166 ammonium sulphate Substances 0.000 abstract description 20
235000011130 ammonium sulphate Nutrition 0.000 abstract description 20
239000002244 precipitate Substances 0.000 abstract description 10
239000000872 buffer Substances 0.000 abstract description 8
238000000108 ultra-filtration Methods 0.000 abstract description 8
239000000284 extract Substances 0.000 abstract description 7
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 4
239000004202 carbamide Substances 0.000 abstract description 4
101710118506 69 kDa protein Proteins 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 20
235000018102 proteins Nutrition 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
235000010633 broth Nutrition 0.000 description 18
239000012528 membrane Substances 0.000 description 18
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 14
239000000203 mixture Substances 0.000 description 10
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 9
229940001007 aluminium phosphate Drugs 0.000 description 9
229910000147 aluminium phosphate Inorganic materials 0.000 description 9
238000005119 centrifugation Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000010451 perlite Substances 0.000 description 8
235000019362 perlite Nutrition 0.000 description 8
238000000746 purification Methods 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
239000006228 supernatant Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
238000000605 extraction Methods 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
230000002480 immunoprotective effect Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
238000001556 precipitation Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
230000002335 preservative effect Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000004224 protection Effects 0.000 description 4
235000019624 protein content Nutrition 0.000 description 4
238000003756 stirring Methods 0.000 description 4
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000011031 large-scale manufacturing process Methods 0.000 description 3
229940066827 pertussis vaccine Drugs 0.000 description 3
229960005323 phenoxyethanol Drugs 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000588779 Bordetella bronchiseptica Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000012465 retentate Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
229940033663 thimerosal Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241000588780 Bordetella parapertussis Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
101710194807 Protective antigen Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229960002713 calcium chloride Drugs 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000003891 ferrous sulphate Nutrition 0.000 description 1
239000011790 ferrous sulphate Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
235000003969 glutathione Nutrition 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002386 leaching Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
239000004223 monosodium glutamate Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
230000031787 nutrient reservoir activity Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000001018 virulence Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

CA002224052A 1990-04-04 1991-04-03 Proteine de la membrane externe de bordetella pertussis Expired - Lifetime CA2224052C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002359307A CA2359307A1 (fr)	1990-04-04	1991-04-03	Proteine de la membrane externe de bordetella pertussis

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB909007656A GB9007656D0 (en)	1989-04-04	1990-04-04	Control system
GB9007656.1		1990-04-04
CA002079887A CA2079887C (fr)	1990-04-04	1991-04-03	Purification d'une proteine de membrane externe de la coqueluche

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002079887A Division CA2079887C (fr)	1990-04-04	1991-04-03	Purification d'une proteine de membrane externe de la coqueluche

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002359307A Division CA2359307A1 (fr)	1990-04-04	1991-04-03	Proteine de la membrane externe de bordetella pertussis

Publications (2)

Publication Number	Publication Date
CA2224052A1 CA2224052A1 (fr)	1991-10-05
CA2224052C true CA2224052C (fr)	2001-12-18

Family

ID=25675568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002224052A Expired - Lifetime CA2224052C (fr)	1990-04-04	1991-04-03	Proteine de la membrane externe de bordetella pertussis

Country Status (1)

Country	Link
CA (1)	CA2224052C (fr)

1991
- 1991-04-03 CA CA002224052A patent/CA2224052C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2224052A1 (fr)	1991-10-05

Legal Events

Date	Code	Title	Description
1998-02-10	EEER	Examination request
2011-04-03	MKEX	Expiry

Publication	Publication Date	Title
EP0527753B2 (fr)	2003-12-17	Purification et utilisation de pertactin, une proteine de la membrane externe de bordetella pertussis
EP0336736B1 (fr)	1994-05-04	Purification de toxines de Pertussis et production de vaccin
AU714493B2 (en)	2000-01-06	Multivalent DTP-polio vaccines
AU715417B2 (en)	2000-02-03	Acellular pertussis vaccines and methods of preparation thereof
US4705686A (en)	1987-11-10	Process for the preparation of acellular Bordetalla pertussis vaccine
AU641711B2 (en)	1993-09-30	Process for purification of a 69 000 dalton antigenetic protein from bordetella pertussis
CA1280693C (fr)	1991-02-26	Purification des antigenes de b. pertussis
Novotny et al.	1991	Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine
EP0175841B1 (fr)	1991-03-06	Méthode de production d'un composant de vaccin contre la coqueluche et vaccin combiné d'antigène de coqueluche, de toxoide de la diphtérie et de toxoide du tétanos
US4774086A (en)	1988-09-27	Process for the purification, solubilization and/or detoxification of protein antigens of bacteria of the Bordetella genus using a carbonate buffer and an acellular anti-whooping cough vaccine
US6444211B2 (en)	2002-09-03	Purification of a pertussis outer membrane protein
CA2224052C (fr)	2001-12-18	Proteine de la membrane externe de bordetella pertussis
WO2009016651A1 (fr)	2009-02-05	Moyens simplifiés pour obtenir une prn à partir de bordetella pertussis
US20010051163A1 (en)	2001-12-13	Purification of a pertussis outer membrane protein
CA2359307A1 (fr)	1991-10-05	Proteine de la membrane externe de bordetella pertussis
CA1188986A (fr)	1985-06-18	Isolation d'une enterotoxine thermostable de e. coli d'origine porcine